HCW BIOLOGICS INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.04 USD | -1.19% |
|
-4.59% | -15.10% |
| May. 16 | HCW Biologics Inc. announced that it expects to receive $10 million in funding | CI |
| May. 15 | HCW Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
| Sales 2024 * | 1.13M | Sales 2025 * | - | Capitalization | 39.34M |
|---|---|---|---|---|---|
| Net income 2024 * | -25M | Net income 2025 * | -29M | EV / Sales 2024 * | 34.9 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.68
x | P/E ratio 2025 * |
-1.89
x | Employees | 45 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 47.7% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.19% | ||
| 1 week | -4.59% | ||
| Current month | -4.59% | ||
| 1 month | -18.75% | ||
| 3 months | -36.20% | ||
| 6 months | -5.45% | ||
| Current year | -15.10% |
1 week
1.00
1.10
1 month
1.001.33
Current year
1.001.93
1 year
0.912.32
3 years
0.917.78
5 years
0.917.78
10 years
0.917.78
| Managers | Title | Age | Since |
|---|---|---|---|
Hing Wong
FOU | Founder | 70 | 18-04-01 |
Rebecca Byam
DFI | Director of Finance/CFO | 68 | 19-09-30 |
Peter Rhode
CTO | Chief Tech/Sci/R&D Officer | 66 | 19-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Scott Garrett
CHM | Chairman | 74 | 21-04-30 |
Hing Wong
FOU | Founder | 70 | 18-04-01 |
Rick Greene
BRD | Director/Board Member | 59 | 21-04-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-06 | 1.04 | -1.19% | 1,719 |
| 24-06-05 | 1.052 | +0.24% | 8,220 |
| 24-06-04 | 1.05 | -3.67% | 2,426 |
| 24-06-03 | 1.09 | 0.00% | 3,082 |
| 24-05-31 | 1.09 | 0.00% | 4,429 |
Delayed Quote Nasdaq, June 06, 2024 at 03:36 pm EDT
More quotes
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions such as long-haul COVID-19. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth factor-β and stimulate immune cells, targeting senescent cells and the SASP factors they secrete. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, and others.
Calendar
2024-06-14
- Annual General Meeting
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.04
USD
Average target price
4
USD
Spread / Average Target
+284.62%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.10% | 39.34M | |
| +18.73% | 125B | |
| +13.45% | 108B | |
| -4.59% | 24.57B | |
| +3.58% | 22.82B | |
| -11.07% | 18.19B | |
| -41.48% | 16.54B | |
| -13.04% | 16.5B | |
| +1.35% | 13.39B | |
| +21.35% | 11.1B |
- Stock Market
- Equities
- HCWB Stock
